India, Brazil, and Ukraine — to make it possible to obtain generic versions of a medicine sold by Vertex Pharmaceuticals. And the coordinated effort underscores the growing global battle over ...

After a lengthy investigation, South African regulators decided Vertex Pharmaceuticals has sufficiently ... different governments – South Africa, India, Brazil and Ukraine – to make it ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...

Vertex Pharmaceuticals Inc. closed 15.20% short of its 52-week high of $519.88, which the company achieved on November 8th.

Vertex Pharmaceuticals’ breakthrough in cystic fibrosis was a medicine that treats just 4% of patients who have the lung disorder. Today, Vertex’s portfolio of blockbuster CF products spans ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having surveyed 35 key opinion leaders who treat a total of ...